SUBSCRIBE
SUBSCRIBE
News   Drug Development

Novo Nordisk A/S (Jobs) Says Liraglutide Data Encouraging

August 20, 2007 | 
1 min read
COPENHAGEN, Aug 20 (Reuters) - Denmark's Novo Nordisk A/S said on Monday two Phase III studies of its hormone analogue Liraglutide had improved glucose control and lowered body weight in diabetes patients, sending its shares higher.
Clinical research Phase 3 Europe
Novo Nordisk
MORE ON THIS TOPIC
Insights
Germany can produce biotech winners. Europe must back them better.
May 27, 2026
 · 
4 min read
 · 
Jennifer C. Smith-Parker
Active construction site with cranes, workers, builders and skyscrapers under development. Process of building. Vector illustration. Line art style. Isometric view of a monolithic frame building.
Manufacturing
Niowave, fresh from Novartis deal, starts building $75M radioisotope plant
May 26, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Concept of saving money with a pink colored piggy bank held in a hand in front of a blackboard with hand drawn coins
Gene editing
Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study
May 26, 2026
 · 
2 min read
 · 
Tristan Manalac
Lung organ anatomy symbol for health and medical illustrations. vector, illustration.
Antibody-drug conjugate (ADC)
Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival
May 22, 2026
 · 
3 min read
 · 
Annalee Armstrong